Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
tRNA (uracil-5-)-methyltransferase homolog A (TRMT2A) is an S-adenosyl-L-methionine-dependent methyltransferase that catalyzes the formation of 5-methyl-uridine (m5U), mainly at position 54 in cytosolic tRNAs, and in some cases in mRNAs[1][2][8]. This modification is important for tRNA stability and function, contributing to translational fidelity and efficient protein synthesis[2][7]. TRMT2A is predicted to function in methylation, tRNA processing, and mRNA processing and is localized primarily to the cytosol[3]. Aberrant expression of TRMT2A has been reported as a possible biomarker in breast mucinous carcinoma, with some evidence for a role in suppressing cell proliferation and regulating the cell cycle[1][5][9]. No approved drugs are currently known to target TRMT2A, nor are there established mechanisms of action or safety concerns associated with therapeutic targeting[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on tRNA (uracil-5-)-methyltransferase homolog A (TRMT2A).